UNSPSC 51286207: Fosfomycin tromethamine

This classification denotes a urinary anti-infective agent with the molecular formula C4H11NO3.C3H7O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7FXW6U30GY, chemically known as phosphonic acid, (3-methyloxiranyl)-, (2r-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) but more generally known as fosfomycin trometamol, which bears US NIH Compound Identifier 54331. European Medicines Agency schedules Fosfomycin trometamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02263MIG.

UNSPSC 51286207 Fosfomycin tromethamine is a Commodity code, but the recent opportunities sourced under it do not center on this specific antibiotic pharmaceutical. Instead, state and local governments are procuring a broad mix of medications, medical supplies, and pharmacy benefit services — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and direct-to-manufacturer prescription fulfillment capabilities. The issuing bodies span health departments, fire departments, state human services commissions, and cooperative purchasing alliances that serve multiple jurisdictions. Work being solicited includes supply agreements for emergency medical consumables (respiratory equipment, cardiac monitoring devices, endotracheal tubes, gloves, oxygen delivery systems), annual purchases of pharmaceutical inventory through state and regional cooperative procurement vehicles, and exploratory direct-contracting relationships between state pharmacy benefit programs and drug manufacturers to bypass traditional pharmacy benefit managers and wholesalers.

Recent activity appears concentrated in Florida, Minnesota, and Texas. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for annual purchases of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the City of Tampa released an IFB on March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000.00, designated as a sheltered market opportunity with a 5 percent bid discount for certified Small Local Business Enterprises; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities, with contracts effective July 1, 2026 and weighted evaluation favoring price competitiveness at 75 percent; and the Texas Health and Human Services Commission issued an RFI on April 3, 2026 for vendor capabilities regarding direct-to-manufacturer prescription programs. The code shows modest recent activity with multiple issuing bodies and no concentration in a single jurisdiction or service line.